Replies to post #130444 on Biotech Values

[DewDiligence]

I would suggest that you’re making something out of almost nothing. The FDA’s draft regs on FoB’s, which are due any day, have to at least be passively endorsed by Congress, which is tantamount to saying that they have to not be undone. Nothing new about that.

I don’t see why an FoB partnership would need to wait for Congressional endorsement. Other companies have already inked FoB partnerships (e.g. Teva-Lonza), so I presume that MNTA can do the same if they are able to reach an agreement with a prospective partner on the profit split from such an endeavor.

This disconnect has me discounting any excitement folks are hearing when CW talks about the FoB program, as if something substantial there is imminent.

On this narrow point, I concur. As previously posted (#msg-68743455), today’s CC does not signal anything in particular, IMO. Regards, Dew